Two novel inhibitory anti-human factor XI antibodies prevent cessation of blood flow in a murine venous thrombosis model

Thrombosis and Haemostasis

Volumn 110, Issue 5, 2013, Pages 1065-1073

  van Montfoort, Maurits L ^a   Knaup, Veronique L ^a   Marquart, J Arnoud ^a   Bakhtiari, Kamran ^a   Castellino, Francis J ^b   Erik Hack, C ^c   Meijers, Joost C M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF NOTRE DAME   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Coagulation; Factor XI; Murine models; Thrombosis

Indexed keywords

ALPHA COAGULATION FACTOR XI 175; ALPHA COAGULATION FACTOR XI 203; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12A; ENOXAPARIN; HEMOLEVEN; PROTEIN ANTIBODY; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING ASSAY; BLEEDING; BLOOD CLOTTING TEST; BLOOD VESSEL OCCLUSION; CONTROLLED STUDY; FEMALE; HUMAN; INFERIOR CAVA VEIN; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; VEIN BLOOD FLOW; VEIN THROMBOSIS;

COAGULATION; FACTOR XI; MURINE MODELS; THROMBOSIS;

ANIMALS; ANTIBODIES, BLOCKING; BLOOD COAGULATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FACTOR XI; FEMALE; HEMOSTASIS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 84886999571     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-05-0429     Document Type: Article

References (33)

1. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-10370.
2. Bauer KA. New anticoagulants. Curr Opin Hematol 2008; 15: 509-515.
3. Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 287S-310S.
4. Muller F, Gailani D, Renne T. FXI and XII as antithrombotic targets. Curr Opin Hematol 2011; 18: 349-355.
5. Bouma BN, Von dem Borne PA, Meijers JC. FXI and protection of the fibrin clot against lysis--a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost 1998; 80: 24-27.
6. Salomon O, Steinberg DM, Koren-Morag N, et al. Reduced incidence of ischaemic stroke in patients with severe FXI deficiency. Blood 2008; 111: 4113-4117.
7. Salomon O, Steinberg DM, Zucker M, et al. Patients with severe FXI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost 2011; 105: 269-273.
8. Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation FXI as a risk factor for venous thrombosis. N Engl J Med 2000; 342: 696-701.
9. Yang DT, Flanders MM, Kim H, et al. Elevated FXI activity levels are associated with an increased odds ratio for cerebrovascular events. Am J Clin Pathol 2006; 126: 411-415.
10. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood 2006; 108: 4045-4051.
11. Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb Haemost 2002; 87: 774-776.
12. Wang X, Cheng Q, Xu L, et al. Effects of factor IX or FXI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005; 3: 695-702.
13. Wang X, Smith PL, Hsu MY, et al. Effects of FXI deficiency on ferric chlorideinduced vena cava thrombosis in mice. J Thromb Haemost 2006; 4: 1982-1988.
14. Zhang H, Lowenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway FXI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010; 116: 4684-4692.
15. Seligsohn U. FXI deficiency in humans. J Thromb Haemost 2009; 7 (Suppl 1): 84-87.
16. Colman RW, Scott CF. When and where is FXI activated by thrombin? Blood 1996; 87: 2089.
17. Von dem Borne PA, Bajzar L, Meijers JC, et al. Thrombin-mediated activation of FXI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-2327.
18. Gailani D, Renne T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J Thromb Haemost 2007; 5: 1106-1112.
19. Lip GY. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. J Thromb Haemost 2011; 9 (Suppl 1): 344-351.
20. Van Es J, Eerenberg ES, Kamphuisen PW, et al. How to prevent, treat, and overcome current clinical challenges of VTE. J Thromb Haemost 2011; 9 (Suppl 1): 265-274.
21. Pendleton RC, Rodgers GM, Hull RD. Established venous thromboembolism therapies: heparin, low molecular weight heparins, and vitamin K antagonists, with a discussion of heparin-induced thrombocytopenia. Clin Chest Med 2010; 31: 691-706.
22. Diaz JA, Obi AT, Myers Jr. DD, Wrobleski SK, Henke PK, Mackman N, et al. Critical review of mouse models of venous thrombosis. Arterioscler Thromb Vasc Biol 2012; 32: 556-562.
23. Hemker HC, Giesen P, AlDieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper-and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-253.
24. Meijers JC, Mulvihill ER, Davie EW, et al. Apple four in human blood coagulation FXI mediates dimer formation. Biochemistry 1992; 31: 4680-4684.
25. Cho J, Furie BC, Coughlin SR, et al. A critical role for extracellular protein disulfide isomerase during thrombus formation in mice. J Clin Invest 2008; 118: 1123-1131.
26. Day SM, Reeve JL, Myers DD, et al. Murine thrombosis models. Thromb Haemost 2004; 92: 486-494.
27. Cheng Q, Tucker EI, Pine MS, et al. A role for FXIIa-mediated FXI activation in thrombus formation in vivo. Blood 2010; 116: 3981-3989.
28. Gailani D, Lasky NM, Broze Jr. GJ. A murine model of FXI deficiency. Blood Coagul Fibrinolysis 1997; 8: 134-144.
29. Renne T, Schmaier AH, Nickel KF, et al. In vivo roles of FXII. Blood 2012; 120: 4296-4303.
30. Puy C, Tucker EI, Wong ZC, et al. FXII promotes blood coagulation independent of FXI in the presence of long chain polyphosphate. J Thromb Haemost 2013; Epub ahead of print.
31. Kravtsov DV, Matafonov A, Tucker EI, et al. FXI contributes to thrombin generation in the absence of FXII. Blood 2009; 114: 452-458.
32. Minnema MC, Friederich PW, Levi M, et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of FXI. In vivo evidence for a role of FXI as an anti-fibrinolytic factor. J Clin Invest 1998; 101: 10-14.
33. Tucker EI, Marzec UM, White TC, et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of FXI. Blood 2009; 113: 936-944.